nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—Estropipate—osteoporosis	0.0776	0.181	CbGbCtD
Solifenacin—CYP3A4—Calcitriol—osteoporosis	0.0776	0.181	CbGbCtD
Solifenacin—CYP3A4—Ergocalciferol—osteoporosis	0.062	0.145	CbGbCtD
Solifenacin—CYP3A4—Raloxifene—osteoporosis	0.0518	0.121	CbGbCtD
Solifenacin—CYP3A4—Ethinyl Estradiol—osteoporosis	0.05	0.117	CbGbCtD
Solifenacin—CYP3A4—Cholecalciferol—osteoporosis	0.04	0.0934	CbGbCtD
Solifenacin—CYP3A4—Conjugated Estrogens—osteoporosis	0.0367	0.0858	CbGbCtD
Solifenacin—CYP3A4—Estradiol—osteoporosis	0.0322	0.0753	CbGbCtD
Solifenacin—Benazepril—MTHFR—osteoporosis	0.0056	0.551	CrCbGaD
Solifenacin—Benazepril—ACE—osteoporosis	0.00456	0.449	CrCbGaD
Solifenacin—Hypertension—Risedronate—osteoporosis	0.000848	0.0016	CcSEcCtD
Solifenacin—Somnolence—Calcitriol—osteoporosis	0.000846	0.0016	CcSEcCtD
Solifenacin—Decreased appetite—Ibandronate—osteoporosis	0.000845	0.0016	CcSEcCtD
Solifenacin—Infestation NOS—Estradiol—osteoporosis	0.000841	0.00159	CcSEcCtD
Solifenacin—Infestation—Estradiol—osteoporosis	0.000841	0.00159	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00084	0.00159	CcSEcCtD
Solifenacin—Depression—Estradiol—osteoporosis	0.000838	0.00158	CcSEcCtD
Solifenacin—Fatigue—Ibandronate—osteoporosis	0.000838	0.00158	CcSEcCtD
Solifenacin—Dysgeusia—Zoledronate—osteoporosis	0.000835	0.00158	CcSEcCtD
Solifenacin—Constipation—Ibandronate—osteoporosis	0.000832	0.00157	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00083	0.00157	CcSEcCtD
Solifenacin—Pruritus—Etidronic acid—osteoporosis	0.000829	0.00157	CcSEcCtD
Solifenacin—Gastrointestinal pain—Estropipate—osteoporosis	0.000829	0.00157	CcSEcCtD
Solifenacin—Decreased appetite—Calcitriol—osteoporosis	0.000828	0.00156	CcSEcCtD
Solifenacin—Mental disorder—Conjugated Estrogens—osteoporosis	0.000826	0.00156	CcSEcCtD
Solifenacin—Feeling abnormal—Alendronate—osteoporosis	0.000823	0.00155	CcSEcCtD
Solifenacin—Malnutrition—Conjugated Estrogens—osteoporosis	0.000821	0.00155	CcSEcCtD
Solifenacin—Dry mouth—Risedronate—osteoporosis	0.000818	0.00154	CcSEcCtD
Solifenacin—Urinary tract infection—Estradiol—osteoporosis	0.000817	0.00154	CcSEcCtD
Solifenacin—Gastrointestinal pain—Alendronate—osteoporosis	0.000817	0.00154	CcSEcCtD
Solifenacin—Infection—Ethinyl Estradiol—osteoporosis	0.000817	0.00154	CcSEcCtD
Solifenacin—Cough—Pamidronate—osteoporosis	0.000815	0.00154	CcSEcCtD
Solifenacin—Constipation—Calcitriol—osteoporosis	0.000814	0.00154	CcSEcCtD
Solifenacin—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000806	0.00152	CcSEcCtD
Solifenacin—Hypertension—Pamidronate—osteoporosis	0.000806	0.00152	CcSEcCtD
Solifenacin—Urticaria—Estropipate—osteoporosis	0.000806	0.00152	CcSEcCtD
Solifenacin—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000804	0.00152	CcSEcCtD
Solifenacin—Vision blurred—Zoledronate—osteoporosis	0.000804	0.00152	CcSEcCtD
Solifenacin—Gastrointestinal pain—Raloxifene—osteoporosis	0.000803	0.00152	CcSEcCtD
Solifenacin—Abdominal pain—Estropipate—osteoporosis	0.000802	0.00151	CcSEcCtD
Solifenacin—Feeling abnormal—Ibandronate—osteoporosis	0.000801	0.00151	CcSEcCtD
Solifenacin—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000798	0.00151	CcSEcCtD
Solifenacin—Infection—Risedronate—osteoporosis	0.000796	0.0015	CcSEcCtD
Solifenacin—Hepatobiliary disease—Estradiol—osteoporosis	0.000795	0.0015	CcSEcCtD
Solifenacin—Gastrointestinal pain—Ibandronate—osteoporosis	0.000795	0.0015	CcSEcCtD
Solifenacin—Urticaria—Alendronate—osteoporosis	0.000793	0.0015	CcSEcCtD
Solifenacin—Abdominal pain—Alendronate—osteoporosis	0.00079	0.00149	CcSEcCtD
Solifenacin—Nervous system disorder—Risedronate—osteoporosis	0.000786	0.00148	CcSEcCtD
Solifenacin—Angioedema—Zoledronate—osteoporosis	0.000779	0.00147	CcSEcCtD
Solifenacin—Skin disorder—Risedronate—osteoporosis	0.000778	0.00147	CcSEcCtD
Solifenacin—Gastrointestinal pain—Calcitriol—osteoporosis	0.000778	0.00147	CcSEcCtD
Solifenacin—Abdominal pain—Raloxifene—osteoporosis	0.000777	0.00147	CcSEcCtD
Solifenacin—Vision blurred—Conjugated Estrogens—osteoporosis	0.000774	0.00146	CcSEcCtD
Solifenacin—Urticaria—Ibandronate—osteoporosis	0.000773	0.00146	CcSEcCtD
Solifenacin—Abdominal pain—Ibandronate—osteoporosis	0.000769	0.00145	CcSEcCtD
Solifenacin—Confusional state—Pamidronate—osteoporosis	0.000768	0.00145	CcSEcCtD
Solifenacin—Anaphylactic shock—Pamidronate—osteoporosis	0.000762	0.00144	CcSEcCtD
Solifenacin—Infection—Pamidronate—osteoporosis	0.000757	0.00143	CcSEcCtD
Solifenacin—Urticaria—Calcitriol—osteoporosis	0.000756	0.00143	CcSEcCtD
Solifenacin—Palpitations—Zoledronate—osteoporosis	0.000754	0.00142	CcSEcCtD
Solifenacin—Abdominal pain—Calcitriol—osteoporosis	0.000753	0.00142	CcSEcCtD
Solifenacin—Angioedema—Conjugated Estrogens—osteoporosis	0.00075	0.00142	CcSEcCtD
Solifenacin—Pharyngitis—Estradiol—osteoporosis	0.000749	0.00142	CcSEcCtD
Solifenacin—Hypersensitivity—Estropipate—osteoporosis	0.000747	0.00141	CcSEcCtD
Solifenacin—Nervous system disorder—Pamidronate—osteoporosis	0.000747	0.00141	CcSEcCtD
Solifenacin—Urinary tract disorder—Estradiol—osteoporosis	0.000745	0.00141	CcSEcCtD
Solifenacin—Vomiting—Etidronic acid—osteoporosis	0.000745	0.00141	CcSEcCtD
Solifenacin—Cough—Zoledronate—osteoporosis	0.000744	0.00141	CcSEcCtD
Solifenacin—Oedema peripheral—Estradiol—osteoporosis	0.000744	0.0014	CcSEcCtD
Solifenacin—Tachycardia—Pamidronate—osteoporosis	0.000744	0.0014	CcSEcCtD
Solifenacin—Connective tissue disorder—Estradiol—osteoporosis	0.000742	0.0014	CcSEcCtD
Solifenacin—Urethral disorder—Estradiol—osteoporosis	0.00074	0.0014	CcSEcCtD
Solifenacin—Rash—Etidronic acid—osteoporosis	0.000739	0.0014	CcSEcCtD
Solifenacin—Dermatitis—Etidronic acid—osteoporosis	0.000738	0.00139	CcSEcCtD
Solifenacin—Hypertension—Zoledronate—osteoporosis	0.000736	0.00139	CcSEcCtD
Solifenacin—Hypersensitivity—Alendronate—osteoporosis	0.000736	0.00139	CcSEcCtD
Solifenacin—Headache—Etidronic acid—osteoporosis	0.000734	0.00139	CcSEcCtD
Solifenacin—Asthenia—Estropipate—osteoporosis	0.000728	0.00137	CcSEcCtD
Solifenacin—Palpitations—Conjugated Estrogens—osteoporosis	0.000726	0.00137	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000721	0.00136	CcSEcCtD
Solifenacin—Pruritus—Estropipate—osteoporosis	0.000717	0.00136	CcSEcCtD
Solifenacin—Asthenia—Alendronate—osteoporosis	0.000717	0.00135	CcSEcCtD
Solifenacin—Hypersensitivity—Ibandronate—osteoporosis	0.000716	0.00135	CcSEcCtD
Solifenacin—Cough—Conjugated Estrogens—osteoporosis	0.000716	0.00135	CcSEcCtD
Solifenacin—Erythema multiforme—Estradiol—osteoporosis	0.000714	0.00135	CcSEcCtD
Solifenacin—Dry mouth—Zoledronate—osteoporosis	0.00071	0.00134	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00071	0.00134	CcSEcCtD
Solifenacin—Fatigue—Ethinyl Estradiol—osteoporosis	0.000709	0.00134	CcSEcCtD
Solifenacin—Pruritus—Alendronate—osteoporosis	0.000707	0.00133	CcSEcCtD
Solifenacin—Dyspepsia—Risedronate—osteoporosis	0.000705	0.00133	CcSEcCtD
Solifenacin—Eye disorder—Estradiol—osteoporosis	0.000705	0.00133	CcSEcCtD
Solifenacin—Constipation—Ethinyl Estradiol—osteoporosis	0.000703	0.00133	CcSEcCtD
Solifenacin—Confusional state—Zoledronate—osteoporosis	0.000702	0.00133	CcSEcCtD
Solifenacin—Hypersensitivity—Calcitriol—osteoporosis	0.000701	0.00132	CcSEcCtD
Solifenacin—Cardiac disorder—Estradiol—osteoporosis	0.000701	0.00132	CcSEcCtD
Solifenacin—Asthenia—Ibandronate—osteoporosis	0.000698	0.00132	CcSEcCtD
Solifenacin—Nausea—Etidronic acid—osteoporosis	0.000696	0.00132	CcSEcCtD
Solifenacin—Anaphylactic shock—Zoledronate—osteoporosis	0.000696	0.00131	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000694	0.00131	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Risedronate—osteoporosis	0.000692	0.00131	CcSEcCtD
Solifenacin—Infection—Zoledronate—osteoporosis	0.000691	0.00131	CcSEcCtD
Solifenacin—Fatigue—Risedronate—osteoporosis	0.000691	0.00131	CcSEcCtD
Solifenacin—Pruritus—Ibandronate—osteoporosis	0.000688	0.0013	CcSEcCtD
Solifenacin—Constipation—Risedronate—osteoporosis	0.000685	0.00129	CcSEcCtD
Solifenacin—Angiopathy—Estradiol—osteoporosis	0.000685	0.00129	CcSEcCtD
Solifenacin—Asthenia—Calcitriol—osteoporosis	0.000683	0.00129	CcSEcCtD
Solifenacin—Nervous system disorder—Zoledronate—osteoporosis	0.000682	0.00129	CcSEcCtD
Solifenacin—Immune system disorder—Estradiol—osteoporosis	0.000682	0.00129	CcSEcCtD
Solifenacin—Mediastinal disorder—Estradiol—osteoporosis	0.00068	0.00128	CcSEcCtD
Solifenacin—Tachycardia—Zoledronate—osteoporosis	0.000679	0.00128	CcSEcCtD
Solifenacin—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000677	0.00128	CcSEcCtD
Solifenacin—Somnolence—Pamidronate—osteoporosis	0.000677	0.00128	CcSEcCtD
Solifenacin—Skin disorder—Zoledronate—osteoporosis	0.000676	0.00128	CcSEcCtD
Solifenacin—Pruritus—Calcitriol—osteoporosis	0.000674	0.00127	CcSEcCtD
Solifenacin—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000672	0.00127	CcSEcCtD
Solifenacin—Dyspepsia—Pamidronate—osteoporosis	0.000671	0.00127	CcSEcCtD
Solifenacin—Dizziness—Estropipate—osteoporosis	0.000671	0.00127	CcSEcCtD
Solifenacin—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00067	0.00127	CcSEcCtD
Solifenacin—Infection—Conjugated Estrogens—osteoporosis	0.000666	0.00126	CcSEcCtD
Solifenacin—Decreased appetite—Pamidronate—osteoporosis	0.000662	0.00125	CcSEcCtD
Solifenacin—Mental disorder—Estradiol—osteoporosis	0.000661	0.00125	CcSEcCtD
Solifenacin—Dizziness—Alendronate—osteoporosis	0.000661	0.00125	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000658	0.00124	CcSEcCtD
Solifenacin—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000657	0.00124	CcSEcCtD
Solifenacin—Malnutrition—Estradiol—osteoporosis	0.000657	0.00124	CcSEcCtD
Solifenacin—Fatigue—Pamidronate—osteoporosis	0.000657	0.00124	CcSEcCtD
Solifenacin—Gastrointestinal pain—Risedronate—osteoporosis	0.000655	0.00124	CcSEcCtD
Solifenacin—Tachycardia—Conjugated Estrogens—osteoporosis	0.000654	0.00124	CcSEcCtD
Solifenacin—Urticaria—Ethinyl Estradiol—osteoporosis	0.000653	0.00123	CcSEcCtD
Solifenacin—Constipation—Pamidronate—osteoporosis	0.000652	0.00123	CcSEcCtD
Solifenacin—Skin disorder—Conjugated Estrogens—osteoporosis	0.000651	0.00123	CcSEcCtD
Solifenacin—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00065	0.00123	CcSEcCtD
Solifenacin—Dizziness—Raloxifene—osteoporosis	0.00065	0.00123	CcSEcCtD
Solifenacin—Vomiting—Estropipate—osteoporosis	0.000645	0.00122	CcSEcCtD
Solifenacin—Dysgeusia—Estradiol—osteoporosis	0.000643	0.00122	CcSEcCtD
Solifenacin—Dizziness—Ibandronate—osteoporosis	0.000643	0.00121	CcSEcCtD
Solifenacin—Rash—Estropipate—osteoporosis	0.000639	0.00121	CcSEcCtD
Solifenacin—Dermatitis—Estropipate—osteoporosis	0.000639	0.00121	CcSEcCtD
Solifenacin—Urticaria—Risedronate—osteoporosis	0.000637	0.0012	CcSEcCtD
Solifenacin—Headache—Estropipate—osteoporosis	0.000635	0.0012	CcSEcCtD
Solifenacin—Vomiting—Alendronate—osteoporosis	0.000635	0.0012	CcSEcCtD
Solifenacin—Abdominal pain—Risedronate—osteoporosis	0.000634	0.0012	CcSEcCtD
Solifenacin—Rash—Alendronate—osteoporosis	0.00063	0.00119	CcSEcCtD
Solifenacin—Dermatitis—Alendronate—osteoporosis	0.000629	0.00119	CcSEcCtD
Solifenacin—Feeling abnormal—Pamidronate—osteoporosis	0.000628	0.00119	CcSEcCtD
Solifenacin—Headache—Alendronate—osteoporosis	0.000626	0.00118	CcSEcCtD
Solifenacin—Vomiting—Raloxifene—osteoporosis	0.000625	0.00118	CcSEcCtD
Solifenacin—Gastrointestinal pain—Pamidronate—osteoporosis	0.000623	0.00118	CcSEcCtD
Solifenacin—Rash—Raloxifene—osteoporosis	0.000619	0.00117	CcSEcCtD
Solifenacin—Dermatitis—Raloxifene—osteoporosis	0.000619	0.00117	CcSEcCtD
Solifenacin—Somnolence—Zoledronate—osteoporosis	0.000619	0.00117	CcSEcCtD
Solifenacin—Vomiting—Ibandronate—osteoporosis	0.000618	0.00117	CcSEcCtD
Solifenacin—Headache—Raloxifene—osteoporosis	0.000615	0.00116	CcSEcCtD
Solifenacin—Rash—Ibandronate—osteoporosis	0.000613	0.00116	CcSEcCtD
Solifenacin—Dermatitis—Ibandronate—osteoporosis	0.000613	0.00116	CcSEcCtD
Solifenacin—Dyspepsia—Zoledronate—osteoporosis	0.000613	0.00116	CcSEcCtD
Solifenacin—Headache—Ibandronate—osteoporosis	0.000609	0.00115	CcSEcCtD
Solifenacin—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000606	0.00114	CcSEcCtD
Solifenacin—Vomiting—Calcitriol—osteoporosis	0.000605	0.00114	CcSEcCtD
Solifenacin—Decreased appetite—Zoledronate—osteoporosis	0.000605	0.00114	CcSEcCtD
Solifenacin—Nausea—Estropipate—osteoporosis	0.000602	0.00114	CcSEcCtD
Solifenacin—Abdominal pain—Pamidronate—osteoporosis	0.000602	0.00114	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000601	0.00113	CcSEcCtD
Solifenacin—Angioedema—Estradiol—osteoporosis	0.0006	0.00113	CcSEcCtD
Solifenacin—Rash—Calcitriol—osteoporosis	0.0006	0.00113	CcSEcCtD
Solifenacin—Fatigue—Zoledronate—osteoporosis	0.0006	0.00113	CcSEcCtD
Solifenacin—Dermatitis—Calcitriol—osteoporosis	0.0006	0.00113	CcSEcCtD
Solifenacin—Headache—Calcitriol—osteoporosis	0.000596	0.00113	CcSEcCtD
Solifenacin—Somnolence—Conjugated Estrogens—osteoporosis	0.000596	0.00113	CcSEcCtD
Solifenacin—Constipation—Zoledronate—osteoporosis	0.000595	0.00112	CcSEcCtD
Solifenacin—Nausea—Alendronate—osteoporosis	0.000593	0.00112	CcSEcCtD
Solifenacin—Hypersensitivity—Risedronate—osteoporosis	0.00059	0.00112	CcSEcCtD
Solifenacin—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00059	0.00111	CcSEcCtD
Solifenacin—Asthenia—Ethinyl Estradiol—osteoporosis	0.00059	0.00111	CcSEcCtD
Solifenacin—Nausea—Raloxifene—osteoporosis	0.000583	0.0011	CcSEcCtD
Solifenacin—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000582	0.0011	CcSEcCtD
Solifenacin—Pruritus—Ethinyl Estradiol—osteoporosis	0.000582	0.0011	CcSEcCtD
Solifenacin—Palpitations—Estradiol—osteoporosis	0.000581	0.0011	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000579	0.00109	CcSEcCtD
Solifenacin—Fatigue—Conjugated Estrogens—osteoporosis	0.000578	0.00109	CcSEcCtD
Solifenacin—Nausea—Ibandronate—osteoporosis	0.000578	0.00109	CcSEcCtD
Solifenacin—Asthenia—Risedronate—osteoporosis	0.000575	0.00109	CcSEcCtD
Solifenacin—Feeling abnormal—Zoledronate—osteoporosis	0.000573	0.00108	CcSEcCtD
Solifenacin—Cough—Estradiol—osteoporosis	0.000573	0.00108	CcSEcCtD
Solifenacin—Constipation—Conjugated Estrogens—osteoporosis	0.000573	0.00108	CcSEcCtD
Solifenacin—Gastrointestinal pain—Zoledronate—osteoporosis	0.000569	0.00107	CcSEcCtD
Solifenacin—Hypertension—Estradiol—osteoporosis	0.000567	0.00107	CcSEcCtD
Solifenacin—Pruritus—Risedronate—osteoporosis	0.000567	0.00107	CcSEcCtD
Solifenacin—Nausea—Calcitriol—osteoporosis	0.000565	0.00107	CcSEcCtD
Solifenacin—Hypersensitivity—Pamidronate—osteoporosis	0.000561	0.00106	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000556	0.00105	CcSEcCtD
Solifenacin—Urticaria—Zoledronate—osteoporosis	0.000553	0.00104	CcSEcCtD
Solifenacin—Abdominal pain—Zoledronate—osteoporosis	0.00055	0.00104	CcSEcCtD
Solifenacin—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000548	0.00103	CcSEcCtD
Solifenacin—Dry mouth—Estradiol—osteoporosis	0.000547	0.00103	CcSEcCtD
Solifenacin—Asthenia—Pamidronate—osteoporosis	0.000547	0.00103	CcSEcCtD
Solifenacin—Dizziness—Ethinyl Estradiol—osteoporosis	0.000544	0.00103	CcSEcCtD
Solifenacin—Confusional state—Estradiol—osteoporosis	0.000541	0.00102	CcSEcCtD
Solifenacin—Pruritus—Pamidronate—osteoporosis	0.000539	0.00102	CcSEcCtD
Solifenacin—Anaphylactic shock—Estradiol—osteoporosis	0.000536	0.00101	CcSEcCtD
Solifenacin—Infection—Estradiol—osteoporosis	0.000533	0.00101	CcSEcCtD
Solifenacin—Urticaria—Conjugated Estrogens—osteoporosis	0.000532	0.00101	CcSEcCtD
Solifenacin—Dizziness—Risedronate—osteoporosis	0.00053	0.001	CcSEcCtD
Solifenacin—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00053	0.001	CcSEcCtD
Solifenacin—Nervous system disorder—Estradiol—osteoporosis	0.000526	0.000993	CcSEcCtD
Solifenacin—Tachycardia—Estradiol—osteoporosis	0.000523	0.000989	CcSEcCtD
Solifenacin—Vomiting—Ethinyl Estradiol—osteoporosis	0.000523	0.000987	CcSEcCtD
Solifenacin—Skin disorder—Estradiol—osteoporosis	0.000521	0.000984	CcSEcCtD
Solifenacin—Rash—Ethinyl Estradiol—osteoporosis	0.000518	0.000979	CcSEcCtD
Solifenacin—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000518	0.000978	CcSEcCtD
Solifenacin—Headache—Ethinyl Estradiol—osteoporosis	0.000515	0.000973	CcSEcCtD
Solifenacin—Hypersensitivity—Zoledronate—osteoporosis	0.000513	0.000968	CcSEcCtD
Solifenacin—Vomiting—Risedronate—osteoporosis	0.00051	0.000962	CcSEcCtD
Solifenacin—Rash—Risedronate—osteoporosis	0.000505	0.000954	CcSEcCtD
Solifenacin—Dermatitis—Risedronate—osteoporosis	0.000505	0.000954	CcSEcCtD
Solifenacin—Dizziness—Pamidronate—osteoporosis	0.000504	0.000952	CcSEcCtD
Solifenacin—Headache—Risedronate—osteoporosis	0.000502	0.000948	CcSEcCtD
Solifenacin—Asthenia—Zoledronate—osteoporosis	0.000499	0.000943	CcSEcCtD
Solifenacin—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000494	0.000933	CcSEcCtD
Solifenacin—Pruritus—Zoledronate—osteoporosis	0.000492	0.00093	CcSEcCtD
Solifenacin—Nausea—Ethinyl Estradiol—osteoporosis	0.000488	0.000922	CcSEcCtD
Solifenacin—Vomiting—Pamidronate—osteoporosis	0.000484	0.000915	CcSEcCtD
Solifenacin—Asthenia—Conjugated Estrogens—osteoporosis	0.000481	0.000908	CcSEcCtD
Solifenacin—Rash—Pamidronate—osteoporosis	0.00048	0.000907	CcSEcCtD
Solifenacin—Dermatitis—Pamidronate—osteoporosis	0.00048	0.000907	CcSEcCtD
Solifenacin—Headache—Pamidronate—osteoporosis	0.000477	0.000902	CcSEcCtD
Solifenacin—Somnolence—Estradiol—osteoporosis	0.000477	0.000901	CcSEcCtD
Solifenacin—Nausea—Risedronate—osteoporosis	0.000476	0.000899	CcSEcCtD
Solifenacin—Pruritus—Conjugated Estrogens—osteoporosis	0.000474	0.000895	CcSEcCtD
Solifenacin—Dyspepsia—Estradiol—osteoporosis	0.000472	0.000892	CcSEcCtD
Solifenacin—Decreased appetite—Estradiol—osteoporosis	0.000466	0.000881	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Estradiol—osteoporosis	0.000463	0.000875	CcSEcCtD
Solifenacin—Fatigue—Estradiol—osteoporosis	0.000462	0.000873	CcSEcCtD
Solifenacin—Dizziness—Zoledronate—osteoporosis	0.00046	0.000869	CcSEcCtD
Solifenacin—Constipation—Estradiol—osteoporosis	0.000459	0.000866	CcSEcCtD
Solifenacin—Nausea—Pamidronate—osteoporosis	0.000453	0.000855	CcSEcCtD
Solifenacin—Dizziness—Conjugated Estrogens—osteoporosis	0.000443	0.000837	CcSEcCtD
Solifenacin—Vomiting—Zoledronate—osteoporosis	0.000442	0.000836	CcSEcCtD
Solifenacin—Feeling abnormal—Estradiol—osteoporosis	0.000442	0.000835	CcSEcCtD
Solifenacin—Rash—Zoledronate—osteoporosis	0.000439	0.000829	CcSEcCtD
Solifenacin—Gastrointestinal pain—Estradiol—osteoporosis	0.000439	0.000828	CcSEcCtD
Solifenacin—Dermatitis—Zoledronate—osteoporosis	0.000438	0.000828	CcSEcCtD
Solifenacin—Headache—Zoledronate—osteoporosis	0.000436	0.000823	CcSEcCtD
Solifenacin—Vomiting—Conjugated Estrogens—osteoporosis	0.000426	0.000805	CcSEcCtD
Solifenacin—Urticaria—Estradiol—osteoporosis	0.000426	0.000805	CcSEcCtD
Solifenacin—Abdominal pain—Estradiol—osteoporosis	0.000424	0.000801	CcSEcCtD
Solifenacin—Rash—Conjugated Estrogens—osteoporosis	0.000422	0.000798	CcSEcCtD
Solifenacin—Dermatitis—Conjugated Estrogens—osteoporosis	0.000422	0.000797	CcSEcCtD
Solifenacin—Headache—Conjugated Estrogens—osteoporosis	0.00042	0.000793	CcSEcCtD
Solifenacin—Nausea—Zoledronate—osteoporosis	0.000413	0.000781	CcSEcCtD
Solifenacin—Nausea—Conjugated Estrogens—osteoporosis	0.000398	0.000752	CcSEcCtD
Solifenacin—Hypersensitivity—Estradiol—osteoporosis	0.000395	0.000746	CcSEcCtD
Solifenacin—Asthenia—Estradiol—osteoporosis	0.000385	0.000727	CcSEcCtD
Solifenacin—Pruritus—Estradiol—osteoporosis	0.000379	0.000717	CcSEcCtD
Solifenacin—Dizziness—Estradiol—osteoporosis	0.000355	0.00067	CcSEcCtD
Solifenacin—Vomiting—Estradiol—osteoporosis	0.000341	0.000644	CcSEcCtD
Solifenacin—Rash—Estradiol—osteoporosis	0.000338	0.000639	CcSEcCtD
Solifenacin—Dermatitis—Estradiol—osteoporosis	0.000338	0.000638	CcSEcCtD
Solifenacin—Headache—Estradiol—osteoporosis	0.000336	0.000635	CcSEcCtD
Solifenacin—Nausea—Estradiol—osteoporosis	0.000319	0.000602	CcSEcCtD
Solifenacin—CHRM1—Signaling by GPCR—PTH—osteoporosis	4.62e-05	0.00141	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PTH—osteoporosis	4.61e-05	0.00141	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PTH—osteoporosis	4.56e-05	0.0014	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	4.51e-05	0.00138	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CNR2—osteoporosis	4.5e-05	0.00138	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	4.5e-05	0.00138	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CNR2—osteoporosis	4.49e-05	0.00137	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	4.46e-05	0.00136	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CNR2—osteoporosis	4.45e-05	0.00136	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—WNT1—osteoporosis	4.23e-05	0.00129	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—WNT1—osteoporosis	4.22e-05	0.00129	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PTHLH—osteoporosis	4.22e-05	0.00129	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PTHLH—osteoporosis	4.2e-05	0.00129	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—TNF—osteoporosis	4.19e-05	0.00128	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—IDH2—osteoporosis	4.19e-05	0.00128	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—WNT1—osteoporosis	4.18e-05	0.00128	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PTHLH—osteoporosis	4.16e-05	0.00127	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—P4HB—osteoporosis	4.16e-05	0.00127	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MGLL—osteoporosis	4.13e-05	0.00126	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MGLL—osteoporosis	4.12e-05	0.00126	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MGLL—osteoporosis	4.08e-05	0.00125	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTH—osteoporosis	4.05e-05	0.00124	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—LRP5—osteoporosis	4.03e-05	0.00123	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LRP5—osteoporosis	4.02e-05	0.00123	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—P4HB—osteoporosis	3.99e-05	0.00122	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RAP1A—osteoporosis	3.98e-05	0.00122	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LRP5—osteoporosis	3.98e-05	0.00122	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CNR2—osteoporosis	3.95e-05	0.00121	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP27A1—osteoporosis	3.94e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—ADCY5—osteoporosis	3.92e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NFATC1—osteoporosis	3.88e-05	0.00119	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTH—osteoporosis	3.88e-05	0.00119	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—LRP6—osteoporosis	3.85e-05	0.00118	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DKK1—osteoporosis	3.85e-05	0.00118	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LRP6—osteoporosis	3.84e-05	0.00118	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PTHLH—osteoporosis	3.83e-05	0.00117	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ACP5—osteoporosis	3.83e-05	0.00117	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PTHLH—osteoporosis	3.82e-05	0.00117	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RAP1A—osteoporosis	3.81e-05	0.00117	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LRP6—osteoporosis	3.81e-05	0.00116	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PTHLH—osteoporosis	3.78e-05	0.00116	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CNR2—osteoporosis	3.78e-05	0.00116	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	3.76e-05	0.00115	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—ADCY5—osteoporosis	3.75e-05	0.00115	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NFATC1—osteoporosis	3.72e-05	0.00114	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CALCA—osteoporosis	3.71e-05	0.00114	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—WNT1—osteoporosis	3.71e-05	0.00113	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CALCA—osteoporosis	3.7e-05	0.00113	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DKK1—osteoporosis	3.69e-05	0.00113	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CALCA—osteoporosis	3.67e-05	0.00112	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—FGA—osteoporosis	3.61e-05	0.0011	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—TPI1—osteoporosis	3.56e-05	0.00109	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—ADCY5—osteoporosis	3.56e-05	0.00109	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—WNT1—osteoporosis	3.55e-05	0.00109	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—FGA—osteoporosis	3.46e-05	0.00106	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—POMC—osteoporosis	3.44e-05	0.00105	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—POMC—osteoporosis	3.43e-05	0.00105	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—ADCY5—osteoporosis	3.41e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—POMC—osteoporosis	3.39e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—IL6—osteoporosis	3.38e-05	0.00103	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CALCA—osteoporosis	3.37e-05	0.00103	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CALCA—osteoporosis	3.36e-05	0.00103	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—BMP2—osteoporosis	3.36e-05	0.00103	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTHLH—osteoporosis	3.36e-05	0.00103	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—P4HB—osteoporosis	3.35e-05	0.00102	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CALCA—osteoporosis	3.33e-05	0.00102	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GAPDH—osteoporosis	3.28e-05	0.001	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—FGB—osteoporosis	3.28e-05	0.001	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TLN1—osteoporosis	3.25e-05	0.000995	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TLN1—osteoporosis	3.24e-05	0.000992	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTHLH—osteoporosis	3.21e-05	0.000983	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—BMP2—osteoporosis	3.21e-05	0.000983	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TLN1—osteoporosis	3.21e-05	0.000983	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—RAP1A—osteoporosis	3.2e-05	0.000978	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PSMA2—osteoporosis	3.17e-05	0.000969	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PSMA5—osteoporosis	3.17e-05	0.000969	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—FGB—osteoporosis	3.14e-05	0.000962	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PSMA2—osteoporosis	3.04e-05	0.000928	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PSMA5—osteoporosis	3.04e-05	0.000928	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CALCA—osteoporosis	2.95e-05	0.000903	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—POMC—osteoporosis	2.88e-05	0.000881	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—POMC—osteoporosis	2.84e-05	0.000868	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CALCA—osteoporosis	2.83e-05	0.000865	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—P4HB—osteoporosis	2.81e-05	0.000858	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—P4HB—osteoporosis	2.8e-05	0.000856	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—IL6—osteoporosis	2.8e-05	0.000855	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—P4HB—osteoporosis	2.77e-05	0.000847	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—POMC—osteoporosis	2.76e-05	0.000844	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTH—osteoporosis	2.73e-05	0.000835	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTH—osteoporosis	2.72e-05	0.000832	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTH—osteoporosis	2.7e-05	0.000824	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RAP1A—osteoporosis	2.68e-05	0.000821	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KL—osteoporosis	2.68e-05	0.00082	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PKM—osteoporosis	2.68e-05	0.000819	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—FDPS—osteoporosis	2.68e-05	0.000819	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RAP1A—osteoporosis	2.67e-05	0.000818	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CNR2—osteoporosis	2.66e-05	0.000814	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CNR2—osteoporosis	2.65e-05	0.000811	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.65e-05	0.00081	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RAP1A—osteoporosis	2.65e-05	0.00081	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—ADCY5—osteoporosis	2.64e-05	0.000808	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.64e-05	0.000807	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—ADCY5—osteoporosis	2.63e-05	0.000805	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CNR2—osteoporosis	2.63e-05	0.000803	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NFATC1—osteoporosis	2.62e-05	0.0008	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—POMC—osteoporosis	2.62e-05	0.0008	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NFATC1—osteoporosis	2.61e-05	0.000798	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—ADCY5—osteoporosis	2.61e-05	0.000797	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DKK1—osteoporosis	2.6e-05	0.000794	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DKK1—osteoporosis	2.59e-05	0.000792	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ENO1—osteoporosis	2.59e-05	0.000791	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NFATC1—osteoporosis	2.58e-05	0.00079	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KL—osteoporosis	2.57e-05	0.000786	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DKK1—osteoporosis	2.56e-05	0.000784	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6R—osteoporosis	2.55e-05	0.00078	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PSMA5—osteoporosis	2.55e-05	0.000779	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PSMA2—osteoporosis	2.55e-05	0.000779	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PGLS—osteoporosis	2.54e-05	0.000776	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPD2—osteoporosis	2.54e-05	0.000776	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—POMC—osteoporosis	2.51e-05	0.000766	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—WNT1—osteoporosis	2.5e-05	0.000765	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—WNT1—osteoporosis	2.49e-05	0.000763	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—WNT1—osteoporosis	2.47e-05	0.000755	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6R—osteoporosis	2.44e-05	0.000747	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FGA—osteoporosis	2.43e-05	0.000744	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FGA—osteoporosis	2.43e-05	0.000742	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FGA—osteoporosis	2.4e-05	0.000735	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ADCY5—osteoporosis	2.4e-05	0.000733	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ADCY5—osteoporosis	2.39e-05	0.000731	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ADCY5—osteoporosis	2.37e-05	0.000724	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PNP—osteoporosis	2.32e-05	0.00071	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ATIC—osteoporosis	2.32e-05	0.00071	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTHLH—osteoporosis	2.26e-05	0.000692	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—BMP2—osteoporosis	2.26e-05	0.000692	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTHLH—osteoporosis	2.26e-05	0.00069	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—BMP2—osteoporosis	2.26e-05	0.00069	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTHLH—osteoporosis	2.23e-05	0.000683	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—BMP2—osteoporosis	2.23e-05	0.000683	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FGB—osteoporosis	2.21e-05	0.000677	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FGB—osteoporosis	2.21e-05	0.000675	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FGB—osteoporosis	2.19e-05	0.000668	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PSMA2—osteoporosis	2.14e-05	0.000654	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PSMA5—osteoporosis	2.14e-05	0.000654	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PSMA2—osteoporosis	2.13e-05	0.000652	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PSMA5—osteoporosis	2.13e-05	0.000652	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PSMA2—osteoporosis	2.11e-05	0.000645	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PSMA5—osteoporosis	2.11e-05	0.000645	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ADCY5—osteoporosis	2.1e-05	0.000643	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP19A1—osteoporosis	2.07e-05	0.000632	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SPP1—osteoporosis	2.03e-05	0.000622	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ADCY5—osteoporosis	2.01e-05	0.000615	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CALCA—osteoporosis	1.99e-05	0.000609	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CALCA—osteoporosis	1.99e-05	0.000607	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CA2—osteoporosis	1.97e-05	0.000604	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—OXCT1—osteoporosis	1.97e-05	0.000604	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CALCA—osteoporosis	1.97e-05	0.000601	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SPP1—osteoporosis	1.95e-05	0.000595	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—POMC—osteoporosis	1.94e-05	0.000594	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—POMC—osteoporosis	1.94e-05	0.000592	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MGLL—osteoporosis	1.92e-05	0.000588	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—POMC—osteoporosis	1.92e-05	0.000586	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IRS2—osteoporosis	1.84e-05	0.000562	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KL—osteoporosis	1.81e-05	0.000553	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KL—osteoporosis	1.8e-05	0.000551	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—LEP—osteoporosis	1.8e-05	0.00055	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KL—osteoporosis	1.79e-05	0.000546	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—POMC—osteoporosis	1.76e-05	0.000539	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IRS2—osteoporosis	1.76e-05	0.000538	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—POMC—osteoporosis	1.76e-05	0.000538	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—POMC—osteoporosis	1.74e-05	0.000533	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—LEP—osteoporosis	1.72e-05	0.000527	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6R—osteoporosis	1.72e-05	0.000526	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ESR1—osteoporosis	1.72e-05	0.000525	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6R—osteoporosis	1.72e-05	0.000525	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6R—osteoporosis	1.7e-05	0.000519	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ADCY5—osteoporosis	1.69e-05	0.000516	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GPX1—osteoporosis	1.68e-05	0.000515	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ESR1—osteoporosis	1.64e-05	0.000503	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—IDH2—osteoporosis	1.64e-05	0.0005	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IRS1—osteoporosis	1.6e-05	0.000491	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—MTHFR—osteoporosis	1.55e-05	0.000475	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—POMC—osteoporosis	1.55e-05	0.000473	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.54e-05	0.00047	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IRS1—osteoporosis	1.54e-05	0.00047	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6R—osteoporosis	1.51e-05	0.000461	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ACP5—osteoporosis	1.5e-05	0.000458	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IGF1—osteoporosis	1.49e-05	0.000455	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—POMC—osteoporosis	1.48e-05	0.000453	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6R—osteoporosis	1.44e-05	0.000442	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IGF1—osteoporosis	1.42e-05	0.000435	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADCY5—osteoporosis	1.42e-05	0.000433	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADCY5—osteoporosis	1.41e-05	0.000432	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADCY5—osteoporosis	1.4e-05	0.000428	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TPI1—osteoporosis	1.39e-05	0.000425	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SPP1—osteoporosis	1.37e-05	0.000419	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SPP1—osteoporosis	1.37e-05	0.000418	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SPP1—osteoporosis	1.35e-05	0.000414	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—P4HB—osteoporosis	1.31e-05	0.0004	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GAPDH—osteoporosis	1.28e-05	0.000393	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—RAP1A—osteoporosis	1.25e-05	0.000382	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—POMC—osteoporosis	1.24e-05	0.00038	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IRS2—osteoporosis	1.24e-05	0.000379	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IRS2—osteoporosis	1.24e-05	0.000378	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IRS2—osteoporosis	1.22e-05	0.000374	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—LEP—osteoporosis	1.21e-05	0.000371	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LEP—osteoporosis	1.21e-05	0.00037	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LEP—osteoporosis	1.2e-05	0.000366	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ESR1—osteoporosis	1.16e-05	0.000354	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ESR1—osteoporosis	1.15e-05	0.000353	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ESR1—osteoporosis	1.14e-05	0.00035	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—osteoporosis	1.14e-05	0.000348	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—osteoporosis	1.09e-05	0.000333	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IRS1—osteoporosis	1.08e-05	0.000331	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IRS1—osteoporosis	1.08e-05	0.00033	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IRS1—osteoporosis	1.07e-05	0.000327	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—POMC—osteoporosis	1.04e-05	0.000319	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—POMC—osteoporosis	1.04e-05	0.000318	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—POMC—osteoporosis	1.03e-05	0.000315	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6R—osteoporosis	1.02e-05	0.000311	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6R—osteoporosis	1.01e-05	0.00031	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ENO1—osteoporosis	1.01e-05	0.000309	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6R—osteoporosis	1e-05	0.000307	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IGF1—osteoporosis	1e-05	0.000307	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IGF1—osteoporosis	9.99e-06	0.000306	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PSMA5—osteoporosis	9.96e-06	0.000305	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PSMA2—osteoporosis	9.96e-06	0.000305	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IGF1—osteoporosis	9.89e-06	0.000303	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—osteoporosis	8.93e-06	0.000273	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—osteoporosis	8.91e-06	0.000273	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—osteoporosis	8.56e-06	0.000262	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—osteoporosis	8.53e-06	0.000261	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP19A1—osteoporosis	8.08e-06	0.000247	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—osteoporosis	7.67e-06	0.000234	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—osteoporosis	7.64e-06	0.000234	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—osteoporosis	7.57e-06	0.000231	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—osteoporosis	6.72e-06	0.000205	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADCY5—osteoporosis	6.6e-06	0.000202	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPX1—osteoporosis	6.58e-06	0.000201	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—osteoporosis	6.43e-06	0.000197	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTHFR—osteoporosis	6.07e-06	0.000186	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—osteoporosis	6.02e-06	0.000184	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—osteoporosis	6.01e-06	0.000184	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—osteoporosis	6e-06	0.000184	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—osteoporosis	5.99e-06	0.000183	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—osteoporosis	5.95e-06	0.000182	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—osteoporosis	5.93e-06	0.000181	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—POMC—osteoporosis	4.86e-06	0.000149	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—osteoporosis	4.53e-06	0.000138	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—osteoporosis	4.51e-06	0.000138	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—osteoporosis	4.47e-06	0.000137	CbGpPWpGaD
